We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
TcLand Expression Launches a Multicenter Clinical Validation Study on Its K-RejX Diagnostic Blood Test
News

TcLand Expression Launches a Multicenter Clinical Validation Study on Its K-RejX Diagnostic Blood Test

TcLand Expression Launches a Multicenter Clinical Validation Study on Its K-RejX Diagnostic Blood Test
News

TcLand Expression Launches a Multicenter Clinical Validation Study on Its K-RejX Diagnostic Blood Test

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TcLand Expression Launches a Multicenter Clinical Validation Study on Its K-RejX Diagnostic Blood Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TcLand Expression SA has announced the launch of the KARE study (Kidney Allograft REjection).

This will be the international, multicentre, prospective clinical validation study for TcLand Expression’s K-RejX qPCR blood test, as a multi-gene molecular diagnostic tool to help in the identification of kidney transplant recipients at risk of chronic antibody-mediated rejection (CAMR). The KARE study will enroll 450 patients from over 30 European and North American large transplantation centers.
Advertisement